Cosyntropin
Cosyntropin is a synthetic ACTH fragment used in adrenal testing. The selected research paper examined a separate experimental obstetric application after accidental dural puncture.
Prescription medicines
Read the studies →
EXPLORE THE BIOLOGY
Content updated · how dates work
Specific hormone disorders and neuroendocrine conditions.
This topic groups related research questions. Shared biology does not make different peptides interchangeable, or establish a clinical benefit. Compare each paper’s population, preparation, and measured outcome.
Each peptide is sorted by the strongest kind of human study among its profile’s selected studies, and the row shows what that study found and who was studied. A higher tier means stronger evidence exists, not that the peptide works for endocrine conditions: the best trial may be small, negative or about a different condition. No doses.
| Peptide | Strongest human evidence in our sources | FDA | Human safety data |
|---|---|---|---|
| FDA-approved medicine (9)Approved for the specific uses on its label, which may not be this goal. | |||
| Cosyntropin | Post-dural-puncture headache prophylaxis study (2010) · Human randomized trial Headache occurred in 33% versus 68.9%; epidural blood patches were required in 11.1% versus 28.9%. Among patients who developed headache, severity and duration were not significantly different. Limitation: This is a small study in a specific procedural setting. It does not establish broad headache treatment, and the prevention results should not be confused with treating an existing headache. Studied: 90 parturients after accidental dural puncture, studied after delivery. | FDA-approved | FDA label |
| Degarelix | PRONOUNCE (2021) · Human randomized trial Major cardiovascular events occurred in 5.5% versus 4.1%: hazard ratio 1.28 (95% CI 0.59–2.79; P=0.53). Limitation: Early termination and fewer events than planned leave cardiovascular superiority unresolved. A nonsignificant comparison is not proof of equivalence. Studied: 545 patients with prostate cancer and atherosclerotic cardiovascular disease; planned enrollment was 900. | FDA-approved | FDA label |
| HCG | HCG and clomiphene in male hypogonadism (2018) · Human randomized comparative trial Testosterone increased in all three groups, without a significant between-group difference. The combined group had a greater reported improvement in symptom scores. Limitation: Short-term hormonal and symptom outcomes should not be converted into pregnancy, live-birth, or long-term fertility claims. Studied: Men with hypogonadism who wished to preserve fertility. | FDA-approved | FDA label |
| Lanreotide | CLARINET (2014) · Human randomized trial Estimated progression-free survival at 24 months was 65.1% versus 33.0%; hazard ratio for progression or death 0.47. Overall survival and quality of life were not significantly different. The hazard ratio’s 95% CI was 0.30–0.73. Treatment-related diarrhea occurred in 26% versus 9%. Limitation: The tumor subtype and receptor status are essential. Slowing progression is not the same as curing cancer, and cannot be generalized to unrelated tumors. Studied: 204 patients with advanced, well/moderately differentiated, nonfunctioning, somatostatin-receptor-positive neuroendocrine tumors. Tumors… | FDA-approved | FDA label |
| Leuprolide | Historical prostate-cancer comparison (1984) · Human randomized trial Hormonal suppression and overall response were similar; adverse-effect patterns differed. One-year survival was not significantly different. Limitation: This is historical evidence against an older comparator, not a ranking of today’s treatment options. Prostate-cancer findings do not establish benefit for every other leuprolide indication. Studied: 199 patients with previously untreated metastatic prostate cancer. | FDA-approved | FDA label |
| Octreotide | PROMID (2009) · Human randomized trial Median time to tumor progression was 14.3 versus 6 months, with a hazard ratio of 0.34. Limitation: Too few deaths had occurred for a confirmatory survival conclusion. Tumor-growth control and relief of hormone-related symptoms are distinct outcomes; tumor subtype remains central. Studied: 85 patients with metastatic, well-differentiated midgut neuroendocrine tumors. | FDA-approved | FDA label |
| Pasireotide | Pasireotide Cushing disease phase 3 study (2012) · Human randomized trial At month six, urinary cortisol normalized without an increase in the assigned regimen in 12 of 82 and 21 of 80 participants. Hyperglycemia-related adverse events occurred in 118 of 162; 74 started glucose-lowering medication. Limitation: A biochemical response in a subset is not a cure for every patient. The trial compared two regimens rather than treatment with placebo. Novartis funded the study. Studied: 162 adults with Cushing disease. | FDA-approved | FDA label |
| Setmelanotide | Setmelanotide in POMC or LEPR deficiency (2020) · Human open-label phase 3 studies with withdrawal periods At least 10% weight loss was reported in 8 of 10 POMC participants and 5 of 11 LEPR participants. Limitation: This was not a full-year parallel placebo-controlled comparison. Small, genetically selected cohorts do not establish effectiveness in common obesity. Studied: 10 participants with POMC deficiency and 11 with LEPR deficiency, aged six years or older. | FDA-approved | FDA label |
| Triptorelin | Combined TEXT / SOFT analysis (2014) · Human randomized combination-treatment trials Five-year disease-free survival was 91.1% versus 87.3%: hazard ratio 0.72. Overall survival was not significantly different. Limitation: The randomized contrast was between endocrine-treatment strategies. Because ovarian suppression had multiple methods, the outcome difference cannot be attributed to triptorelin alone. Studied: 4,690 premenopausal women with hormone-receptor-positive early breast cancer in the combined analysis. | FDA-approved | FDA label |
| Randomized human trials (1)At least one randomized or placebo-controlled trial, which may be small, negative or about another condition. | |||
| TRH (thyrotropin-releasing hormone) | TRH for cancer-related fatigue (2012) · Human randomized crossover pilot trial Energy ratings and the fatigue and vigor scores improved with TRH compared with placebo, along with fatigue-related quality of life. TRH caused brief rises in blood pressure and heart rate. Limitation: Only eight patients completed the study, effects were measured over hours to a day, and no larger trial has confirmed the result. It does not show benefit for fatigue in people without cancer or with longer use. Studied: Eight adults with cancer and significant fatigue without a reversible medical cause. | Withdrawn | Trials only |
| Small or uncontrolled human studies (3)Human reports without randomization, such as pilots, case series or open-label studies. | |||
| Gonadorelin | Multicenter pulsatile GnRH clinical series (1990) · Human clinical series Reported ovulation rates were 91% in primary and 96% in secondary amenorrhea. Multiple pregnancies occurred in 12%; intravenous-line complications averaged 7%. Limitation: These are results from a clinical series, not a randomized estimate of benefit versus another treatment. Specialist monitoring and the precise diagnosis are part of the clinical context. Studied: 109 women with primary or secondary hypothalamic amenorrhea. | Withdrawn | Very limited |
| Kisspeptin-54 | Kisspeptin-54 triggering of egg maturation (2014) · Human dose-ranging study Egg maturation was observed, and fertilization with embryo transfer occurred in 49 of 53 participants. The study reported 12 clinical pregnancies. Limitation: This was not a head-to-head comparison with a standard trigger. Clinical pregnancy is also different from a proven live-birth advantage. Studied: 53 women undergoing IVF. | Not approved | Very limited |
| Thymulin | Zinc status and thymulin activity (1988) · Human physiological study Thymulin activity was lower in zinc-deficient settings and was restored with zinc in the reported in-vivo and in-vitro experiments. Limitation: These findings do not establish clinical benefit from injecting thymulin or treating people who are not zinc deficient. Studied: 14 participants across experimentally induced zinc deficiency, sickle-cell anemia, and other clinical groups. | Not approved | None |
Selected studies, not a systematic review. Approval belongs to a specific product and use. Compare two side by side on the comparison pages.
Cosyntropin is a synthetic ACTH fragment used in adrenal testing. The selected research paper examined a separate experimental obstetric application after accidental dural puncture.
Prescription medicines
Read the studies →Degarelix is a GnRH antagonist used in prostate-cancer hormone therapy. PRONOUNCE examined cardiovascular events against leuprolide but ended before its planned enrollment.
Prescription medicines
Read the studies →Gonadorelin is gonadotropin-releasing hormone. A clinical series studied pulsatile administration in women with hypothalamic amenorrhea, a specific reproductive-hormone disorder.
Research topics
Read the studies →Human chorionic gonadotropin is a glycoprotein hormone involved in reproductive signaling. The featured study compared hormonal approaches in men with hypogonadism seeking to preserve fertility.
Research topics
Read the studies →Kisspeptin-54 is a reproductive-signaling peptide studied as an egg-maturation trigger during IVF. It is a distinct form from the shorter kisspeptin-10 already covered in this directory.
Research topics
Read the studies →Lanreotide is a prescription somatostatin analogue used in specific endocrine and neuroendocrine conditions. Its evidence depends on the disease being treated.
Prescription medicines
Read the studies →Leuprolide is a GnRH agonist used to control sex-hormone signaling in several conditions. It belongs to a different pathway from growth-hormone secretagogues.
Prescription medicines
Read the studies →Octreotide is a somatostatin-related medicine used in specialist endocrine and gastrointestinal care. Immediate- and long-acting preparations have different roles.
Prescription medicines
Read the studies →Pasireotide is a somatostatin analogue studied in Cushing disease. The selected trial measured cortisol control and reported frequent hyperglycemia-related events.
Prescription medicines
Read the studies →Setmelanotide is a melanocortin-4 receptor agonist studied in rare genetic forms of obesity. The featured trials enrolled people with POMC or LEPR deficiency, rather than general-population obesity.
Prescription medicines
Read the studies →Thymulin is a thymic peptide whose biological activity depends on zinc. The featured human study examined zinc status and thymulin activity; it was not a trial of thymulin injections.
Research topics
Read the studies →TRH is one of the body's own hormones: a tiny peptide made in the brain that tells the pituitary gland to release thyroid-stimulating hormone. A synthetic version, protirelin, was long used in a hospital test of thyroid and pituitary function. Researchers have also studied it in small trials for fatigue, depression and nerve diseases.
Research topics
Read the studies →Triptorelin is a GnRH agonist used for hormone suppression in clinical settings. The featured breast-cancer analysis included several ways of achieving ovarian suppression.
Prescription medicines
Read the studies →See something wrong on this page? Report a mistake · Corrections